Guangzhou, China – Guangdong Dongguangyang Pharmaceutical Co., Ltd. (Stock Code: 06887.HK, hereinafter referred to as "Dongguangyang Pharma") has been awarded the First Prize of the 2023 Guangdong Provincial Science and Technology Progress Award for its groundbreaking project, Key Technological Innovations and Industrialization of Anti-Infective Drug Research and Development. This prestigious accolade, conferred by the Department of Science and Technology of Guangdong Province, recognizes the company’s exceptional contributions to addressing critical public health challenges through scientific innovation.

Project Background and Significance

Infectious diseases account for over 25% of global mortality (WHO, 2020), with annual healthcare expenditures for moderate-to-severe infections exceeding $570 billion. Viral hepatitis and influenza remain among the most prevalent infectious diseases in China, while antimicrobial resistance and severe bacterial infections pose escalating threats to public health. Dongguangyang Pharma’s project addresses three urgent scientific challenges:

1. Original Drug Development: Pioneering novel anti-infective therapies for unmet clinical needs.
2. Preclinical Evaluation: Establishing advanced in vitro and in vivo models for efficacy and safety assessment.
3. Manufacturing Innovation: Optimizing scalable synthesis and production processes for global accessibility.

Key Achievements

• Intellectual Property: 160 authorized patents (including 90 international patents) and 37 peer-reviewed publications.
• Pipeline Milestones: 9 Class 1 innovative drugs in clinical trials; Oseltamivir (branded as Kewei), a WHO-recommended influenza treatment, holds over 50% of the global erythromycin API market, supplying leading pharmaceutical companies such as Abbott and Pfizer.
• Commercial Impact: Generated over RMB 6.6 billion in revenue in the past three years; Kewei series products are utilized in over 1,000 tertiary hospitals nationwide, including Peking Union Medical College Hospital and Sun Yat-sen University-affiliated institutions.

Corporate Vision and Strategic Growth

Since its establishment in 2003, Dongguangyang Pharma has prioritized innovation and globalization, evolving into a fully integrated pharmaceutical enterprise with end-to-end capabilities in R&D, production, and commercialization. The company’s diversified pipeline spans infectious diseases, chronic conditions, and oncology, featuring:

• 45 Class 1 innovative drugs in development.
• 3 New Drug Applications (NDAs) under regulatory review.
• 10 candidates in Phase II/III clinical trials.

Dr. Zhang Yingjun, Chairman of Dongguangyang Pharma, stated: "This award underscores our unwavering commitment to advancing healthcare through scientific excellence. As we continue to expand our global footprint, we remain dedicated to delivering transformative therapies that address the world’s most pressing medical needs."

Recent Milestones

• Merger Completion: On August 7, 2025, Dongguangyang Pharma finalized its merger with Dongguangyang Changjiang Pharmaceutical, solidifying its position as a listed entity on the Hong Kong Stock Exchange (06887.HK).
• Strategic Collaboration: In November 2024, the company partnered with 3SBio Inc. to commercialize benzenesulfonic acid creflotinib, a next-generation FLT3 inhibitor for acute myeloid leukemia (AML), in mainland China.